Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

340B Reform Remains Elusive Even As Spending Increases

Executive Summary

Total purchases at 340B prices by 2021 are projected to exceed $23 bil – more than total Medicare Part B drug reimbursement in 2014.

You may also be interested in...



Pricing Deregulation: 340B Pharmacy Policy, Medicaid Payment Rules May Be Withdrawn

Trump administration's drug pricing action plan considers withdrawing guidance and whole or parts of rules that biopharma has opposed.

340B Freeze: 'Mega-Guidance' Withdrawn; Clarity On Program Boundaries Delayed Again

Long-delayed effort to define key boundaries for 340B drug discount program is on hold once again – and it may now take legislation to enable HRSA to move forward with plans to better define who is eligible for the discount.

340B Impact: Roche Starts Educating Investors About Discount

The 340B hospital discount program has a much higher profile in the Rx policy world than it did before the Affordable Care Act was signed into law; now, Roche is starting to highlight the impact of the program to a different audience: its investors.

Related Content

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel